S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Forecast, Price & News

$435.69
-2.96 (-0.67%)
(As of 09/22/2023 ET)
Compare
Today's Range
$434.44
$440.72
50-Day Range
$450.27
$556.67
52-Week Range
$317.06
$564.73
Volume
439,118 shs
Average Volume
452,336 shs
Market Capitalization
$36.16 billion
P/E Ratio
46.25
Dividend Yield
N/A
Price Target
$571.67

IDEXX Laboratories MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
31.2% Upside
$571.67 Price Target
Short Interest
Bearish
3.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.09
Upright™ Environmental Score
News Sentiment
0.69mentions of IDEXX Laboratories in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$26.74 M Sold Last Quarter
Proj. Earnings Growth
14.36%
From $9.82 to $11.23 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

119th out of 968 stocks

Diagnostics & Research Industry

2nd out of 3 stocks


IDXX stock logo

About IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDXX Price History

IDXX Stock News Headlines

His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
IDEXX Laboratories: Long-Term Growth Remains Attractive
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
20 Most Dog Friendly Cities in the US
Analysis Of IDEXX Laboratories' Recent Earnings
Goldman Sachs Remains a Buy on Idexx Laboratories (IDXX)
Idexx Laboratories (IDXX) Receives a Hold from Stifel Nicolaus
See More Headlines
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Company Calendar

Last Earnings
8/01/2023
Today
9/22/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostics & Research
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
11,000
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$571.67
High Stock Price Forecast
$610.00
Low Stock Price Forecast
$500.00
Forecasted Upside/Downside
+29.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$679.09 million
Pretax Margin
28.49%

Debt

Sales & Book Value

Annual Sales
$3.37 billion
Cash Flow
$9.24 per share
Book Value
$7.35 per share

Miscellaneous

Free Float
81,249,000
Market Cap
$36.54 billion
Optionable
Optionable
Beta
1.20

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Jonathan J. MazelskyMr. Jonathan J. Mazelsky (Age 62)
    Pres, CEO & Director
    Comp: $2.04M
  • Mr. Brian P. McKeonMr. Brian P. McKeon (Age 61)
    CFO, Exec. VP & Treasurer
    Comp: $1.06M
  • Mr. James F. PolewaczykMr. James F. Polewaczyk (Age 59)
    Exec. VP & Chief Commercial Officer
    Comp: $889.99k
  • Mr. Michael J. LaneMr. Michael J. Lane (Age 55)
    Exec. VP and GM of Reference Laboratories & Information Technology
    Comp: $891.1k
  • Dr. Nimrata Khatra Hunt P.E. (Age 55)
    Ph.D., Exec. VP of Strategy, Sector Devel. & Global Operations
    Comp: $887.77k
  • Mr. John Hart
    Sr. VP of Global Operations
  • Mr. Jeffery D. Chadbourne (Age 47)
    Sr. Director of Accounting & Financial Reporting
  • Dr. Martin Smith Ph.D. (Age 55)
    Exec. VP & CTO
  • Mr. Ken Grady
    Sr. VP & Chief Information Officer
  • Ms. Sharon E. Underberg (Age 62)
    Exec. VP, Gen. Counsel, & Corp. Sec.













IDXX Stock - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IDXX shares.
View IDXX analyst ratings
or view top-rated stocks.

What is IDEXX Laboratories' stock price forecast for 2023?

6 analysts have issued 1 year target prices for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $500.00 to $610.00. On average, they anticipate the company's stock price to reach $571.67 in the next twelve months. This suggests a possible upside of 29.9% from the stock's current price.
View analysts price targets for IDXX
or view top-rated stocks among Wall Street analysts.

How have IDXX shares performed in 2023?

IDEXX Laboratories' stock was trading at $407.96 at the beginning of the year. Since then, IDXX stock has increased by 7.9% and is now trading at $440.24.
View the best growth stocks for 2023 here
.

Are investors shorting IDEXX Laboratories?

IDEXX Laboratories saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,480,000 shares, an increase of 8.3% from the August 15th total of 2,290,000 shares. Based on an average daily trading volume, of 454,100 shares, the short-interest ratio is presently 5.5 days. Currently, 3.0% of the shares of the company are sold short.
View IDEXX Laboratories' Short Interest
.

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our IDXX earnings forecast
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings data on Tuesday, August, 1st. The company reported $2.67 EPS for the quarter, topping analysts' consensus estimates of $2.43 by $0.24. The company earned $943.63 million during the quarter, compared to analyst estimates of $927.84 million. IDEXX Laboratories had a net margin of 22.52% and a trailing twelve-month return on equity of 104.84%.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories updated its FY 2023 earnings guidance on Tuesday, August, 1st. The company provided earnings per share (EPS) guidance of $9.64-$9.90 for the period, compared to the consensus estimate of $9.69. The company issued revenue guidance of $3.66 billion-$3.71 billion, compared to the consensus revenue estimate of $3.67 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (188.52%), BlackRock Inc. (10.42%), State Street Corp (4.54%), Alliancebernstein L.P. (4.33%), Geode Capital Management LLC (2.42%) and Franklin Resources Inc. (1.74%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $440.24.

How much money does IDEXX Laboratories make?

IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $36.54 billion and generates $3.37 billion in revenue each year. The company earns $679.09 million in net income (profit) each year or $9.42 on an earnings per share basis.

How many employees does IDEXX Laboratories have?

The company employs 11,000 workers across the globe.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.

This page (NASDAQ:IDXX) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -